LAB International licenses Fentanyl Taifun for Japan

By Lisa Kerner

Erie, Pa., Jan. 11 - LAB International Inc. announced that Teikoku Seiyaku Co. Ltd. will bring its Fentanyl Taifun fast-acting Fentanyl formulation to market in Japan under a licensing and development agreement with its LAB Pharma Ltd. subsidiary.

Under terms of the agreement, Teikoku Seiyaku will be responsible for the further development of Fentanyl Taifun in Japan, building on LAB's development plan for European and North American markets.

LAB will receive a signing fee, development milestone payments and research and development reimbursements for development activities it conducts in support of the development in Japan.

Teikoku Seiyaku will pay LAB royalties on sales and manufacturing revenues for supplying the finished product.

"Teikoku Seiyaku, with its experience in opiate products and drug delivery differentiated products, represents an ideal partner for LAB to bring Fentanyl Taifun through clinical development and regulatory submissions in the Japanese market," Halvor Jaeger, chief executive officer of LAB International, said in a company news release.

Fentanyl is an opiate analgesic commonly used for the treatment of chronic pain associated with conditions such as cancer. Fentanyl Taifun consists of a dry powder formulation of Fentanyl delivered by LAB's proprietary Taifun dry powder inhaler. The development program of Fentanyl Taifun is currently in clinical phase 2 in cancer patients in Europe, according to the release.

Teikoku Seiyaku, based in Sanbonmatsu, Kagawa, Japan, manufactures medicated plasters, including anti-inflammatory and analgesic plasters.

LAB International, an integrated drug development company based in Laval, Quebec, includes LAB Pharma and LAB Research. LAB Pharma is focused on the inhalation market and therapeutic products for asthma, COPD, and growth hormone deficiencies. LAB Research is the contract research services division.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.